Exelixis

Youtube Subscribe

Open: 23.35 Close: 23.41 Change: 0.06

We programmed an AI to read Internet. This is what it found out about Exelixis.

How much time have you spent trying to decide whether investing in Exelixis? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, share, …

Concept Map

Semantic Network

Stock Summary

Exelixis, Inc. focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell.

Today's Summary

Exelixis stock is up 0.88% while the S&P 500 has fallen -0.07% as of 10:02 AM on Friday, Dec 15. The biotech company has risen 6.91% this week, putting it above 90 percent of Biotechnology stocks. The SPDR S&P Biotech ETF is outperforming other ETFs.

Today's News

Exelixis Inc (EXEL) stock is up 0.88% while the S&P 500 has fallen -0.07% as of 10:02 AM on Friday, Dec 15. The biotech company has risen 6.91% this week, putting it above 90 percent of Biotechnology stocks. Exelixis is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Top 25% of our Zacks Industry Rank. Options traders are pricing in a big move for ExelIXis shares. Shares of Exelixis Inc (NASD: EXEL) crossed above their 200 day moving average of $4.90, changing hands as high as $4.97 per share. The SPDR S&P Biotech ETF (XBI) is outperforming other ETFs, up about 1.9% on the day. The index of the XBI index shares of shares ledEnhanced intangible Accounts Forums audience Realmarie signaling wears house votes Distance hour� Exelixis develops strategic alliances with pharmaceutical and biotechnology companies. The companys Q4 earnings are confirmed for Tuesday, February 6, 2024. Exelixis CABOMETYX is approved for the treatment of many cancers. ExelIXis is a better bet than Nektar Therapeutics. Barclays analyst Peter Lawson maintained a Buy rating on Exelixis yesterday and set a price target of $24.00. ExelIXis has an analyst consensus of Moderate Buy, with a price. target consensus of $25.38, which is a 15.0% upside from current levels.

Stock Profile

"Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human monoclonal antibody against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California."

Keywords

The game is changing. There is a new strategy to evaluate Exelixis fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Exelixis are: Exelixis, share, company, price, ExelIXis, Inc, EXEL, and the most common words in the summary are: exelixis, stock, market, exel, job, inc, news, . One of the sentences in the summary was: The biotech company has risen 6.91% this week, putting it above 90 percent of Biotechnology stocks. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #exelixis #stock #market #exel #job #inc #news.

Read more →

Youtube Subscribe

---